An Epidemiological Study of Hyperhidrosis
WILLIAM LEAR, BSC, MD, EDWARD KESSLER, BA,y NOWELL SOLISH, MD, FRCPC,
DEE ANNA GLASER, MDy
AND
BACKGROUND Hyperhidrosis affects approximately 3% of the population. The nature of those patients
presenting for treatment has not been well studied, however.
OBJECTIVE The objective was to perform a descriptive, multicenter study of patterns of patients referred for treatment of focal hyperhidrosis.
METHODS AND MATERIALS A convenience sampling of consecutive patients referred for consideration
of BTX-A therapy was surveyed.
RESULTS A total of 508 patient records (266 patients from Canada; 242 from the United States) were
reviewed; 62.8% of those patients were female. The most common presentation was axillary hyperhidrosis in 73.0% of patients. Most of the patients were moderately to severely affected by their hyperhidrosis, with Hyperhidrosis Disease Severity Scale scores of 3 or 4. There were trends found of facial
and scalp hyperhidrosis affecting more men than women and being triggered by food much more
frequently than in other sites of hyperhidrosis.
CONCLUSION This study has demonstrated novel findings, especially in the differing presentations of
hyperhidrosis between men and women.
Drs. Solish and Glaser are paid speakers and have performed research for Allergan.
H
yperhidrosis is a disorder characterized as
perspiration in excess of the body’s physiologic
need and can significantly impact one’s occupational, physical, emotional, and social life.1,2 Hyperhidrosis is delineated into two classifications of either
primary or secondary hyperhidrosis. Primary hyperhidrosis is distinguished as a chronic, idiopathic
disorder of excessive perspiration in a bilateral,
symmetrical manner.3 Primary hyperhidrosis has
been associated with hyperactivity of the sympathetic nervous system and can affect the palms, soles,
axillae, face, and scalp as well as other areas.2,3
Secondary hyperhidrosis is due to an underlying
condition, such as an infection, endocrine
disorders, metabolic disorders, neoplastic diseases,
neurologic conditions, spinal cord injuries, cardiovascular disorders, respiratory disorders, anxiety,
and stress.2,4
Primary hyperhidrosis is a relatively common disorder, affecting nearly 3% of the population, with the
highest prevalence rates among those aged 18 to
54 years.2 The most common sites of primary hyperhidrosis are palms, soles, axillae, face, and
scalp.4,5 Various treatments for hyperhidrosis exist,
ranging from topical treatments, iontophoresis, oral
anticholinergics, botulinum toxin injections, and
surgery.5–8 A genetic component has been suggested
to contribute to primary hyperhidrosis as family
history has been positive in 30% to 65% of patients.5,9
Much of the current knowledge and research on this
disease has been directed on treatment, while few
studies have devoted much interest in describing the
population subset impacted by hyperhidrosis. Thus,
this study set out with the purpose to identify the
The Cosmetic Care and Laser Surgery Center, Women’s College Hospital, Toronto, Ontario, Canada; yDepartment of
Dermatology, Anheuser-Busch Institute, Saint Louis University School of Medicine,
St. Louis, Missouri
& 2007 by the American Society for Dermatologic Surgery, Inc. Published by Blackwell Publishing
ISSN: 1076-0512 Dermatol Surg 2007;33:S69–S75 DOI: 10.1111/j.1524-4725.2006.32334.x
S69
AN EPIDEMIOLOGIC STUDY OF HYPERHIDROSIS
nature of this population subset by identifying
common trends and associations. This study was
carried out across two clinical populations of
Canada and the United States. A retrospective review
was conducted on medical records of patients affected by hyperhidrosis that presented to either a
specialty hyperhidrosis clinic or a university practice
with interests in describing the most common presentations of hyperhidrosis and significant associations.
Taken as a whole, 62.8% of the patients were
female, as 60.5% of those presenting to the Canadian clinic were female compared to 65.3% at the
American clinic (Table 1). The mean age of the
Canadian patients at date of consultation was 30.3
TABLE 1. Patient Demographics
Clinic
Demographic
Methods
We reviewed the medical records of patients presenting to an urban Canadian hyperhidrosis clinic
and a Midwestern American outpatient dermatology
clinic between July 2003 and December 2005 for
diagnosis and treatment of hyperhidrosis. Information collected from the medical records includes the
following: sex, sites of hyperhidrosis, age, date of
birth, age of onset, aggravating factors, pre- or
postpuberty onset, severity of disease on Hyperhidrosis Disease Severity Scale (HDSS), family history,
handedness, tobacco or alcohol use, social status,
general habitus, occupation, ethnicity, and past
treatment. Data on ethnicity, occupation, social status, tobacco or alcohol use, and general habitus were
not collected at the Canadian clinic.
The results were compiled using the Statistical Package for the Social Sciences (SPSS) and analyzed for
descriptive statistics. The data were grouped into
nominal categories for all variables, except HDSS
and age, which were analyzed as ordinal variables.
Chi-square statistics were used to test differences
between men and women, age of onset, puberty onset, and sites of hyperhidrosis against all other variables. A significance threshold of p o .05 was used to
determine significance throughout this article.
Results
In all, a total of 508 patient medical records were
reviewed between the Canadian and American clinics (266 in Canada and 242 in the United States).
S70
D E R M AT O L O G I C S U R G E RY
American Canadian Combined
(n = 242) (n = 266) (N = 508)
Sex (%)
Female
65.3
Male
34.7
Age at consult (years)
Mean
28.11
SD
12.29
Age of onset (years)
Mean
14.05
Dominant handedness (%)
Left
8.1
Site(s) of hyperhidrosis (%)
Axillary site
78.5
Palmar
47.9
Plantar (soles)
44.6
Face or scalp
23.6
Groin
12.4
13.6
Additionaly
Severity on HDSS (%)
4
79.1
3
20.0
2
0.9
1
0.0
Family history (%)
Positive
47.5
Negative
35.0
Unaware
17.5
Past treatment (%)
Over-the-counter
83.9
Topical aluminum 66.1
chloride
Oral anticholiner- 11.1
gic
Botulinum toxin
8.3
type A
Iontophoresis
11.9
Surgery
0.4
None
3.7
60.5
39.5
62.8
37.2
30.3
10.0
29.3
11.1
F
F
4.9
6.4
68.0
44.0
38.0
22.9
6.4
6.0
73.0
45.9
41.1
22.8
9.3
9.6
35.0
47.7
16.9
0.4
55.2
35.0
9.6
0.2
40.2
59.8
F
43.7
48.0
F
F
73.7
F
70.1
8.3
9.6
18.8
13.8
10.5
4.5
18.8
11.2
2.6
11.6
Each category does not exclude additional sites that may also be
involved.
y
Additional site(s) include patients presenting with (patients are included only once even if multiple sites affected): back, chest, abdomen, forearm, genitals, and lower extremities.
LEAR ET AL
years (SD, 10.0 years) whereas those presenting to
the American clinic were a mean age of 28.1 years
(SD, 12.29 years) with a median age of 25 years (see
Table 1). The mean age of onset of hyperhidrosis for
the American patients was 14 years (median, 13.0
years; SD, 8.25 years; see Table 1).
For both the American and the Canadian clinics, the
most common affected sites were axillary, palmar,
and plantar sites (Table 1). An overwhelming majority of the Canadian and American patients were
moderately or severely affected by hyperhidrosis,
rating their disease as either 3 or 4 on the HDSS
(Table 1).
Many patients noted a positive family history, with
43.7% of the pooled patient population reporting a
relative to be affected by hyperhidrosis (Table 1).
Most patients of either nationality had tried some
form of treatment before the consult visit, such as
topical aluminum chloride (AlCl3; 70.1% of the
combined clinics) or botulinum toxin type A subcutaneous injections (13.8% of the combined clinics;
see Table 1). Only 6.4% of the combined clinics’
patients reported left-handedness, with 4.9% of the
Canadian patients indicating left-handedness compared to 8.1% of the American patients (see Table 1).
An overwhelming majority of the American patients
were Caucasian (87.9%), followed by AfricanAmericans (8.4%), Asians (1.7%), Hispanics
(0.8%), Indian (0.8%), and other (0.4%; Table 2).
The American patient population was divided categorically as (in order of descending frequency):
students, business workers, professionals, home
workers, laborers, retirees, disabled persons, travelers, security, and unemployed persons (Table 2).
Some of the most common aggravating factors reported by patients of either clinic were stress, heat,
and exercise (Table 3).
Several factors were noted to be significant in the
associations of affected site(s) with gender and aggravating factors in both the Canadian and the
American clinics. In both countries, it was noted that
TABLE 2. Ethnicity and Occupation
Ethnicity (%)
Caucasian
87.9
African-American
8.4
Asian
1.7
Hispanic
0.8
Indian
0.8
Other
0.4
Occupation (%)
Student (elementary, high school,
43.4
college, or graduate)
23.8
Business (business professionals, office
workers, salesmen/women, accountants,
processors, representatives, designers,
artists, receptionists, reporters, stylists,
computer workers)
Professional (teachers/professors, attorneys, 15.1
physicians, nurses, professional assistants,
therapists, researchers, administrators,
engineers)
Home (housewives, at-home mothers,
5.0
homemakers)
Labor (construction, factory workers,
4.2
grocery workers, technicians, pipefitters)
Retired
2.5
Drive/travel (stewards/stewardess, couriers,
1.7
truck drivers)
Security (firemen/women, police officers,
1.7
and security officers)
Unemployed
1.2
Disabled
0.84
Data available for American clinic only.
men were significantly more likely to present with
facial or scalp hyperhidrosis. Men presenting to the
American clinic were also found to be significantly
more likely to present with ‘‘additional areas’’ of
hyperhidrosis than women (Table 4). ‘‘Additional
areas’’ refer to the back, chest, abdomen, forearm,
genital, and lower extremities. In contrast, women
presenting to the Canadian clinic were significantly
more likely to have plantar hyperhidrosis than men,
but at a rate similar to American women (Table 4).
Also when considering isolated affected sites of hyperhidrosis, women in the American clinic were
significantly more likely to present with isolated
axillary hyperhidrosis than men. Moreover, women
presenting to the Canadian clinic showed a trend to
present more with axillary hyperhidrosis. This may
have reflected the higher likelihood of women in the
3 3 : S 1 : J A N U A RY 2 0 0 7
S71
AN EPIDEMIOLOGIC STUDY OF HYPERHIDROSIS
cial and scalp hyperhidrosis were significantly more
likely to list food, exercise, and heat as aggravating
factors.
TABLE 3. Aggravating Factors
Clinic
Factor
Anxiety or stress
Heat
Exercise
Food
Sleep
Othery
None
Othery/no known
factors
American
(n = 242)
Canadian
(n = 266)
75.2
61.6
55.4
F
16.5
14.5
8.7
23.1
69.5
64.7
43.2
12.8
F
F
F
24.1
Data are reported as percent.
y
Other aggravating factors refer to winter season, humidity, cold,
caffeine, movement, sitting, clothing, writing, working, and social
situations.
Canadian clinic to have already tried AlCl3 before
consultation.
In the American clinic, patients that presented with
hyperhidrosis of palms, soles (plantar), or a combination of palms and soles (palmoplantar) were significantly more likely to list stress and anxiety as
aggravating factors. Patients that presented with fa-
Other factors noted to be significant in the American
clinic concerned family history of hyperhidrosis.
Patients that presented with palmar, plantar, or palmoplantar hyperhidrosis were significantly more
likely to have a positive family history of hyperhidrosis. Patients that reported the onset of hyperhidrosis before the age of 20 years were significantly
more likely to have a positive family history of hyperhidrosis than those reporting the onset of hyperhidrosis after the age of 20 years old.
Also in the American clinic, patients presenting with
axillary hyperhidrosis were significantly more likely
to have a postpuberty onset of hyperhidrosis. In a
similar manner, when considering isolated affected
sites of hyperhidrosis, a postpuberty onset was significantly more likely in patients presenting with
isolated axillary hyperhidrosis. In contrast, patients
presenting with isolated palmoplantar hyperhidrosis
were significantly more likely to have a prepuberty
onset of hyperhidrosis.
TABLE 4. Cross-section of Site(s) of Hyperhidrosis and Hyperhidrosis Disease Severity Scale (HDSS)
Scores by Sex
Clinic
American
Male
Sitey
Axillary
Palmar
Face or scalp
Plantar (soles)
Groin
Additional areasy
HDSS score
1 or 2
3 or 4
63/84
46/84
26/84
37/84
10/84
18/84
Canadian
Female
(75.0)
(54.8)
(31.0)z
(44.0)
(11.9)
(21.4)z
1/77 (1.3)
76/77 (98.7)
127/158
70/158
23/158
71/158
20/158
15/158
Male
(80.4)
(44.3)
(14.6)z
(44.9)
(12.7)
(9.5)z
1/158 (0.7)
157/158 (99.3)
65/105
41/105
39/105
27/105
6/105
7/105
Female
(61.9)
(39.0)
(37.1)z
(25.7)z
(5.7)
(6.6)
30/105 (28.6)
75/105 (71.4)
116/161
76/161
20/161
74/161
11/161
9/161
(72.0)
(47.2)
(12.4)z
(46.0)z
(6.8)
(5.6)
16/161 (9.9)
145/161 (90.1)
Data are reported as number (%).
y
For each affected site, other sites may also be involved.
Statistically significant, po.05.
Additional areas include patients presenting with (patients are included only once even if multiple sites affected): back, chest, abdomen,
forearm, genitals, and lower extremities.
z
y
S72
D E R M AT O L O G I C S U R G E RY
LEAR ET AL
TABLE 5. Cross-section of Site(s) of Hyperhidrosis
by Age of Onset
Age of onset (years)
Site
y
Axillary
Palmoplantar
Palmar
Plantar (soles)
Face or scalp
Groin
Additional areasy
0–11
12–19
50
53
59
59
17
10
10
101
33
45
42
20
18
15
(27.2)
(58.2)z
(51.8)z
(55.7)z
(37.0)
(33.3)
(31.3)
(54.9)z
(36.3)
(39.5)
(39.6)
(43.5)
(60.0)
(46.9)
20–53
33
5
10
5
9
2
7
(17.9)
(5.5)
(8.8)
(4.7)
(19.6)
(6.7)
(21.9)
Data available for American clinic only. Data are reported as num-
ber (%).
For each affected site, other sites may also be involved. For those
patients with multiple affected sites, age of onset does not specify
which site of hyperhidrosis occurred first and which occurred at a
later date.
z
Statistically significant, po.05.
y
Additional areas include patients presenting with (patients are included only once even if multiple sites affected): back, chest, abdomen, forearm, genitals, and lower extremities.
y
The younger age of onset group (before the age of 11
years) was significantly more likely to present with
hyperhidrosis of the palms, soles, or combined
palmoplantar sites. Patients reporting onset between
the ages of 12 and 19 years were significantly
more likely to present with axillary hyperhidrosis
(Table 5).
Of those presenting to the Canadian locale, higher
HDSS scores were seen in women, but the scores did
not differ among sites of hyperhidrosis. HDSS scores
were significantly higher among patients having tried
prior treatments with aluminum chloride and oral
therapies. Lower HDSS scores were significantly associated with no prior treatments (not shown).
American men and women had similar HDSS scores,
both higher than the Canadians, but did not significantly differ between the sexes.
Discussion
The patient population in our study differed with
the population described in the US prevalence study
by Strutton and colleagues.2 In particular, our
study found an earlier mean age of onset of hyperhidrosis (14 years) compared that reported in the US
prevalence study (25 years). Interestingly, the
mean age of our patients presenting with hyperhidrosis was 29.3 years (28.1 years in the American
clinic and 30.3 years in the Canadian clinic) in
contrast to the study by Strutton and colleagues2
in which the mean age of their study subjects was
40 years.
In addition, we encountered a more severely affected
group of hyperhidrosis patients than expected in
general. The majority of the patients presenting to
the Canadian site reported a HDSS score of 3
whereas the majority of patients in the American
clinic rated their hyperhidrosis with maximum severity (4 of 4) on the HDSS, which rates the disease
as intolerable and always interferes in their life. This
contrasts with the US prevalence study, which reported the majority of the responders with excessive
sweating rated their disease as a 2 (tolerable, sometimes interferes) on the HDSS. The majority of the
presenting patients to either clinic had received numerous therapies before consultation; such a population would be expected to have a higher HDSS
score than an average hyperhidrosis patient in the
community (see Table 1). The difference between the
presenting patients in this study versus those
screened in the study by Strutton and colleagues2
may be due to our study patients actively seeking
treatment for their condition while those described
in the US prevalence study were assessed as the
population at large.
This reasoning may also be extended to explain the
higher percentage of patients in this study affected by
axillary hyperhidrosis (73.0% of the combined clinic
populations vs. 50.8% in the study by Strutton and
coworkers2 study). In addition, there was a difference in the presentation of sex in this study; female
patients presented in higher frequencies in both the
Canadian and the American sites, 62.8% of the
combined clinics (Table 1). Strutton and colleagues2
found no difference among sex and prevalence rates
of hyperhidrosis, but noted the women report their
hyperhidrosis to physicians at higher rates. In addition, a subgroup analysis of the Canadian patients
3 3 : S 1 : J A N U A RY 2 0 0 7
S73
AN EPIDEMIOLOGIC STUDY OF HYPERHIDROSIS
revealed that the women had higher HDSS scores
than men, indicating that they were more severely
affected than males. In the study by Strutton and
coworkers,2 overall female HDSS scores are quite
similar to those of men, making a fundamental difference in interpretation of hyperhidrosis severity
between men and women unlikely. As such, our
finding of such a difference in presentation may be
reflected in the vast disparity between women and
men in discussing their condition with a physician.
Pursuing this suggestion leaves us to consider that
there is some subset of the men affected by hyperhidrosis that have not been referred or sought
treatment for their condition.
In light of this idea, this study found several differences between sexes among the other variables collected. One difference between men and women
related to the affected site(s) of presentation. In
Table 4, the analysis reveals that men were more
likely to present with facial or scalp hyperhidrosis, or
hyperhidrosis in ‘‘additional areas,’’ such as the
chest, back, or lower extremities, than were women.
Facial and scalp hyperhidrosis in these men was aggravated significantly more frequently by food, heat,
and exercise than hyperhidrosis of other sites. Although a full understanding of the pathophysiology
of hyperhidrosis is lacking, there is evidence implicating a heightened sympathetic activity through the
T2 and T3 ganglia resulting in palmar hyperhidrosis.5 To some extent, the degree of autonomic dysfunction can be quantified by the rate of rewarming
of the hands after immersion in an ice bath, with a
slower rate of rewarming being indicative of excessive sympathetic activity.9 Further work has elucidated sex differences in these autonomic responses
between men and women, with women showing
slower baseline rewarming responses than men.10
Although we did not find that more women presented with palmar hyperhidrosis in our population,
there may be further sex differences in autonomic
responses that predispose each sex to have a
higher propensity to develop focal hyperhidrosis in
certain sites, such as the facial hyperhidrosis more
prevalent in men.
S74
D E R M AT O L O G I C S U R G E RY
In the American clinic, although 47.5% of the patients were able to identify a relative with hyperhidrosis, 35.0% reported a negative family history and
17.5% reported not knowing their family history in
regard to hyperhidrosis. Hyperhidrosis in family
members may be underreported due to the social
ramifications and efforts to conceal its presence by
affected family members. American patients who
reported an age of onset before 20 years of age were
found to be more likely to have a positive family
history of hyperhidrosis than those with a later age
of onset. This analysis may be confounded, however,
by the small number of patients reporting a later age
of onset (39 patients) compared to those reporting an
onset before the age of 20 (196 patients).
As was expected in this study, American patients
stating an age of onset between 0 and 11 years were
more likely to present with palmar, plantar, or palmoplantar hyperhidrosis, whereas those reporting an
age of onset between 12 and 19 years were more
likely to present with axillary hyperhidrosis (Table 5).
Supporting this expectation of postpuberty onset of
axillary hyperhidrosis, it was also noted that a postpuberty onset was more likely with patients presenting with axillary hyperhidrosis and hyperhidrosis
isolated only to the axillae. To contrast, a prepuberty
onset was found to be more likely of patients presenting with isolated palmoplantar hyperhidrosis.
In summary, this is the first large descriptive study of
patients seeking diagnosis and treatment of hyperhidrosis, which has demonstrated novel findings. In
contrast to those with excessive sweating in the
community, patients seeking medical attention are
severely affected by their condition. As previously
reported, axillary hyperhidrosis accounts for the
majority of bodily presentation sites. Despite past
reports of no differences between men and women in
regard to the prevalence of excessive sweating, our
study found distinct differences between men
and women in reference to facial or scalp hyperhidrosis and how often they seek medical care for
their hyperhidrosis. There was a clear pattern
in the body site affected by the hyperhidrosis
LEAR ET AL
and the age onset and family history. And although
there were some small differences between the
Canadian and American patients, overall, the
similarities in sex, age seeking treatment, age of onset, and body sites affected were remarkable. Hopefully, these data will help clinicians and future
investigators to better understand the hyperhidrosis
population.
References
1. Lowe N, Campanati A, Bodokh I, et al. The place of botulinum
toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol
2004;151:1115–22.
2. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of
hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol
2004;51:241–8.
3. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad
Dermatol 2004;51:274–86.
4. Eisenach JH, Atkinson JL, Fealey RD. Hyperhidrosis: evolving
therapies for a well-established phenomenon. Mayo Clin Proc
2005;80:657–66.
5. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. Can Med Assoc J 2005;172:69–75.
6. Naumann M, Hamm H. Treatment of axillary hyperhidrosis.
Br J Surg 2002;89:259–61.
7. Baumann L, Slezinger A, Halem M, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy
of Myobloc (botulinum toxin type B) for the treatment of palmar
hyperhidrosis. Dermatol Surg 2005;31:263–70.
8. Glogau RG. Treatment of hyperhidrosis with botulinum toxin.
Dermatol Clin 2004;22:177–85.
9. Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg
2002;35:382–6.
10. Fronek KS, Schmelz M, Kruger S, et al. Effects of gender and level
of surgical sympathetic block on vasoconstrictor function. Clin
Auton Res 2003;13:(Suppl 1):74–8.
11. Schick CH, Fronek K, Held A, et al. Differential effects of surgical
sympathetic block on sudomotor and vasoconstrictor function.
Neurology 2003;60:1770–6.
Address correspondence and reprint requests to:
Dr. Nowell Solish, The Cosmetic Care and Laser Surgery
Center, Women’s College Hospital, 76 Grenville Street,
8th Floor, Toronto, ON, Canada M5S 1B2, or
e-mail: n.solish@utoronto.ca.
3 3 : S 1 : J A N U A RY 2 0 0 7
S75